CompanyASNDNasdaqHellerup

Ascendis Pharma A/S

Ascendis Pharma develops therapeutics using TransCon technology, a prodrug approach that extends drug half-life.

SEC EDGAR ClinicalTrials.gov ascendispharma.com

8-KSep 30Latest SEC filing

Sep 30Latest story

August 2026

BioMarin and Ascendis settle global patent dispute over Yuviwel

Aug 31PartnershipAscendis Pharma A/S Biomarin Pharmaceutical Inc

Ascendis Pharma posts Q2 2026 revenue of €315 million, up 105% year over year

Aug 13Clinical readoutAscendis Pharma A/S navepegritide

Ascendis Pharma Bone's Yorvipath gets labeling supplement approved by FDA

Aug 3Regulatory decisionAscendis Pharma A/S palopegteriparatide

July 2026

Ascendis Pharma registers Phase 3 trial of Yorvipath in adolescent hypoparathyroidism

Jul 16Trial updateAscendis Pharma A/S palopegteriparatide